Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer

Knific, Tamara; Vouk, Katja; Smrkolj, Špela; Prehn, Cornelia; Adamski, Jerzy; Rižner, Tea Lanišnik

doi:10.1016/j.jsbmb.2018.01.012

Cited by 48 publications

(49 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, metabolomics have demonstrated certain metabolites to be associated with histological subtypes [29,30], with recurrence following surgery [29], and with tumor blood flow in EC patients [31]. A recent study has also evaluated plasma sphingomyelins and phosphatidylcholines as biomarkers in EC [32], proposing ratios between specific metabolites as diagnostic and prognostic models. A diagnostic biomarker signature has also been proposed based on urine metabolomics profiling in EC [33].…”

Section: Discussionmentioning

confidence: 99%

Blood Metabolites Associate with Prognosis in Endometrial Cancer

et al. 2019

View full text Add to dashboard Cite

Endometrial cancer has a high prevalence among post-menopausal women in developed countries. We aimed to explore whether certain metabolic patterns could be related to the characteristics of aggressive disease and poorer survival among endometrial cancer patients in Western Norway. Patients with endometrial cancer with short survival (n = 20) were matched according to FIGO (International Federation of Gynecology and Obstetrics, 2009 criteria) stage, histology, and grade, with patients with long survival (n = 20). Plasma metabolites were measured on a multiplex system including 183 metabolites, which were subsequently determined using liquid chromatography-mass spectrometry. Partial least square discriminant analysis, together with hierarchical clustering, was used to identify patterns which distinguished short from long survival. A proposed signature of metabolites related to survival was suggested, and a multivariate receiver operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.820–0.965 (p ≤ 0.001). Methionine sulfoxide seems to be particularly strongly associated with poor survival rates in these patients. In a subgroup with preoperative contrast-enhanced computed tomography data, selected metabolites correlated with the estimated abdominal fat distribution parameters. Metabolic signatures may predict prognosis and be promising supplements when evaluating phenotypes and exploring metabolic pathways related to the progression of endometrial cancer. In the future, this may serve as a useful tool in cancer management.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood Metabolites Associate with Prognosis in Endometrial Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Metabolomic biomarkers associated with LVSI include hexadecadienyl carnitine, phosphatidylcholine with diacyl residue sum C38:1, phosphatidylcholine with diacyl residue sum C34:4 and phosphatidylcholine with acyl-alkyl residue sum C38:3 [76]. A prognostic model incorporating the ratio between two phosphatidylcholines, PC C34:4 and PC C38:3, and the ratio between acylcarnitine C16:2 and phosphatidylcholine PC C38:1 demonstrated a sensitivity of 88.9%, specificity of 84.3% and AUC of 0.94 for LVSI [98]. Audet-Walsh and colleagues explored the potential of endogenous estrogens and their metabolites to serve as EC prognostic biomarkers and reported 2-Methoxyestradiol-glucoronide (2-MeOE2-3G) to be upregulated in EC cases with deep myometrial invasion, while Estrone sulphate was downregulated in cases with LVSI [100].…”

Section: Blood-based Predictive and Prognostic Metabolomic Ec Biomarkersmentioning

confidence: 98%

“…Knific and colleagues, using electrospray ionisation-tandem mass spectrometry on plasma samples obtained from 61 women with EC and 65 controls quantified 163 metabolites [98]. They reported phosphatidylcholines to be significantly downregulated in EC.…”

Section: Blood-based Diagnostic Metabolomic Ec Biomarkersmentioning

confidence: 99%

“…Some metabolites have been associated with the depth of myometrial invasion, specifically hydroxysphingomyelins, phosphatidylcholines and endogenous estrogen metabolites [98]. In the study by Knific and colleagues, a prognostic model for deep myometrial invasion was developed based on the ratio between two hydroxysphingomyelins, SMOH C14:1 and SMOH C24:1, and the ratio between two phosphatidylcholines, PC C40:2 and PC C42:6 [98]. This model demonstrated a sensitivity of 81.3%, specificity of 86.4% and AUC of 0.86 [98].…”

Section: Blood-based Predictive and Prognostic Metabolomic Ec Biomarkersmentioning

confidence: 99%

“…In the study by Knific and colleagues, a prognostic model for deep myometrial invasion was developed based on the ratio between two hydroxysphingomyelins, SMOH C14:1 and SMOH C24:1, and the ratio between two phosphatidylcholines, PC C40:2 and PC C42:6 [98]. This model demonstrated a sensitivity of 81.3%, specificity of 86.4% and AUC of 0.86 [98]. Sphingolipids are bio-effector molecules implicated in cell growth, proliferation and anti-cancer therapeutics [107], whilst phospholipids form the bilayer components of cellular membranes and are involved in malignant transformation and tumour progression [108].…”

Section: Blood-based Predictive and Prognostic Metabolomic Ec Biomarkersmentioning

confidence: 99%

See 2 more Smart Citations

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.

show abstract

Screening tests for endometrial cancer in the general population

Njoku

O’Flynn

Jones

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:To assess the diagnostic accuracy of potential screening tests for the detection of atypical hyperplasia (pre-cancer) and endometrial cancer of all stages and grades in asymptomatic (healthy) women in the general population. Secondary objectives• To determine the optimal endometrial thickness cut-o value using transvaginal ultrasound scan for the screening of asymptomatic women for endometrial cancer and atypical hyperplasia. • To investigate sources of heterogeneity in endometrial cancer screening studies, including: * characteristics of the studied population including age, menopausal status (pre-and postmenopausal), country of study and risk status (body mass index (BMI) categories, diabetes mellitus, polycystic ovary syndrome (PCOS)); * characteristics of index test such as cytological classification used and sampling device; * methodological quality (low risk of bias compared to high risk of bias); * disease factors (endometrioid versus non-endometrioid, low grade versus high grade).

show abstract

Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer

Cited by 48 publications

References 61 publications

Blood Metabolites Associate with Prognosis in Endometrial Cancer

Blood Metabolites Associate with Prognosis in Endometrial Cancer

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

Screening tests for endometrial cancer in the general population

Contact Info

Product

Resources

About